Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group. Di Biagio A, et al. Among authors: zoncada a. J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21. J Antimicrob Chemother. 2013. PMID: 22915463
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups. Morsica G, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592. J Acquir Immune Defic Syndr. 2009. PMID: 19590432
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Torti C, et al. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. BMC Infect Dis. 2011. PMID: 21266068 Free PMC article. Clinical Trial.
A novel methodology for large-scale phylogeny partition.
Prosperi MC, Ciccozzi M, Fanti I, Saladini F, Pecorari M, Borghi V, Di Giambenedetto S, Bruzzone B, Capetti A, Vivarelli A, Rusconi S, Re MC, Gismondo MR, Sighinolfi L, Gray RR, Salemi M, Zazzi M, De Luca A; ARCA collaborative group. Prosperi MC, et al. Nat Commun. 2011;2:321. doi: 10.1038/ncomms1325. Epub 2011 May 24. Nat Commun. 2011. PMID: 21610724 Free PMC article.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.
Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium. Prosperi MC, et al. J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. J Antimicrob Chemother. 2011. PMID: 21624929
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.
Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A; ARCA cohort. Prosperi MC, et al. BMC Med Inform Decis Mak. 2011 Jun 14;11:40. doi: 10.1186/1472-6947-11-40. BMC Med Inform Decis Mak. 2011. PMID: 21672248 Free PMC article.
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype.
Franzetti M, Lai A, Simonetti FR, Bozzi G, De Luca A, Micheli V, Meraviglia P, Corsi P, Bagnarelli P, Almi P, Zoncada A, Balotta C. Franzetti M, et al. Among authors: zoncada a. J Antimicrob Chemother. 2012 May;67(5):1250-3. doi: 10.1093/jac/dks013. Epub 2012 Feb 1. J Antimicrob Chemother. 2012. PMID: 22302564 Free article.
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain. De Luca A, et al. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315324
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C. Santoro MM, et al. Among authors: zoncada a. HIV Med. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13. HIV Med. 2013. PMID: 23668660 Free article.
43 results